Intra-Cellular Therapies’ surging antipsychotic Caplyta has scored again with remarkable trial results, fueling its bid for a third and potentially most lucrative indication—major depressive disorder ...

Wall Street is loving this. Analysts at JPMorgan and RBC Capital see this as a major boost for Intra-Cellular's long-term game plan. CAPLYTA's extended revenue runway has turned heads, with ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

Getting therapeutics into joints in a targeted and sustained fashion is difficult Intra-articular injection solves the delivery problem and brings several additional advantages over systemic ...